To validate the results obtained through MS, the levels of AACT and C4BPα were assessed in exosomal-enriched samples isolated with ExoQ, from both Controls and individuals with dementia, including AD cases, from the UA-cohort and the UMG-cohort. This evidence concerns the gene SERPINA3 and Alzheimer disease.